Sartorius Stedim Biotech S.A. (EPA:DIM)
France · Delayed Price · Currency is EUR 171.20
+1.10 (0.65%)
Jul 31, 2026, 2:43 PM CET
Sartorius Stedim Biotech Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 203.9 | 426.1 | 678.9 | 116.6 | 107.1 | 223.6 |
Cash & Short-Term Investments | 203.9 | 426.1 | 678.9 | 116.6 | 107.1 | 223.6 |
Cash Growth | -70.84% | -37.24% | 482.25% | 8.87% | -52.10% | 274.15% |
Accounts Receivable | 273.2 | 192.8 | 265.9 | 293.7 | 404.6 | 356 |
Inventory | 714.3 | 690.9 | 684.9 | 882.4 | 1,025 | 783 |
Other Current Assets | 161.3 | 131.4 | 111.3 | 122.4 | 134.8 | 93 |
Total Current Assets | 1,353 | 1,441 | 1,741 | 1,415 | 1,671 | 1,456 |
Net Property, Plant & Equipment | 2,064 | 2,025 | 1,885 | 1,633 | 1,292 | 928.4 |
Other Intangible Assets | 1,500 | 1,537 | 1,632 | 1,693 | 876.8 | 684.4 |
Goodwill | 2,894 | 2,884 | 2,908 | 2,885 | 1,136 | 820.7 |
Long-Term Investments | 20.9 | 19 | 24 | 40.8 | 24.9 | 14.8 |
Other Long-Term Assets | 85.7 | 78.8 | 66.5 | 62.6 | 64.1 | 47.2 |
Total Assets | 7,918 | 7,984 | 8,256 | 7,730 | 5,065 | 3,951 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 288.8 | 277.8 | 310 | 258.5 | 485.6 | 471.2 |
Accrued Expenses | 90.5 | 99.1 | 88.2 | 62.3 | 74.1 | 97.2 |
Current Portion of Long-Term Debt | 289.9 | 557.3 | 39.5 | 57.7 | 4.5 | 25.5 |
Current Portion of Leases | 24.9 | 23.4 | 25 | 21.4 | 19.5 | 14.9 |
Unearned Revenue | 182.8 | 167.6 | 216.1 | 238.6 | - | - |
Other Current Liabilities | 289.4 | 287 | 260.1 | 298.8 | 452.1 | 428.3 |
Total Current Liabilities | 1,166 | 1,412 | 938.8 | 937.3 | 1,036 | 1,037 |
Long-Term Debt | 1,942 | 1,867 | 2,684 | 3,510 | 1,021 | 521.1 |
Long-Term Leases | 146.1 | 151.2 | 120.6 | 93.1 | 91.1 | 64 |
Other Long-Term Liabilities | 416.5 | 427.2 | 488.8 | 516.2 | 403.5 | 595.7 |
Total Long-Term Liabilities | 2,504 | 2,446 | 3,294 | 4,119 | 1,515 | 1,181 |
Total Liabilities | 3,671 | 3,858 | 4,233 | 5,056 | 2,551 | 2,218 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 19.5 | 19.5 | 19.5 | 18.4 | 18.4 | 18.4 |
Additional Paid-in Capital | 1,424 | 1,424 | 1,424 | 231.5 | 231.5 | 231.5 |
Retained Earnings | 2,793 | 2,647 | 2,543 | 2,389 | 2,199 | 1,406 |
Total Common Shareholders' Equity | 4,237 | 4,091 | 3,987 | 2,639 | 2,449 | 1,656 |
Minority Interest | 10 | 35.6 | 37.2 | 35.3 | 64.9 | 77.4 |
Shareholders' Equity | 4,247 | 4,126 | 4,024 | 2,674 | 2,514 | 1,733 |
Total Liabilities & Equity | 7,918 | 7,984 | 8,256 | 7,730 | 5,065 | 3,951 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2,403 | 2,599 | 2,870 | 3,682 | 1,136 | 625.5 |
Net Cash (Debt) | -2,199 | -2,173 | -2,191 | -3,565 | -1,029 | -401.9 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -22.69 | -22.34 | -22.64 | -38.69 | -11.16 | -4.36 |
Book Value | 4,237 | 4,091 | 3,987 | 2,639 | 2,449 | 1,656 |
Book Value Per Share | 43.73 | 42.04 | 41.19 | 28.63 | 26.58 | 17.96 |
Tangible Book Value | -157.2 | -330 | -553 | -1,940 | 436.1 | 150.8 |
Tangible Book Value Per Share | -1.62 | -3.39 | -5.71 | -21.05 | 4.73 | 1.64 |